Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Is kidney injury a reversible process?

Christos Chatziantoniou1, Jean-Claude Dussaule

  • 1INSERM U702, Université Pierre et Marie Curie, Paris, France. christos.chatziantoniou@chusa.jussieu.fr

Current Opinion in Nephrology and Hypertension
|December 20, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovering New Therapies for Kidney Fibrosis: The Promise of Epigenetic and Epitranscriptomic Modulation.

Journal of the American Society of Nephrology : JASN·2026
Same author

Fibroblast-derived neuropilin 1 alleviates renal fibrosis progression.

The Journal of pathology·2025
Same author

FAM20C and FAM20A in normal and ectopic mineralization: A focus on oro-renal syndromes.

Matrix biology : journal of the International Society for Matrix Biology·2025
Same author

Differences in biopsy-proven diabetic kidney disease in individuals from Polynesia vs mainland France: a retrospective cohort study.

Diabetologia·2025
Same author

The differential expression of MAGI2 in glomerulopathies and its application as a molecular discriminator of podocytopathies.

Journal of translational medicine·2025
Same author

Advances and challenges in kidney fibrosis therapeutics.

Nature reviews. Nephrology·2025
Same journal

Sex differences in renal acid-base regulation.

Current opinion in nephrology and hypertension·2026
Same journal

Primary prevention of chronic kidney disease in type 2 diabetes mellitus with sodium-glucose cotransporter 2 inhibitors.

Current opinion in nephrology and hypertension·2026
Same journal

Financial and policy challenges of delivering kidney replacement therapies in resource-limited settings.

Current opinion in nephrology and hypertension·2026
Same journal

The role of kir4.1/Kir5.1 in mediating the effect of angiotensin-II on Na-Cl-cotransporter.

Current opinion in nephrology and hypertension·2026
Same journal

Role of the calcium-sensing receptor in regulating calcium transport in the thick ascending limb.

Current opinion in nephrology and hypertension·2026
Same journal

Social determinants of chronic kidney disease: from association to clinical and population action.

Current opinion in nephrology and hypertension·2026
See all related articles

Renal fibrosis progression is reversible. Novel therapies targeting simultaneous proliferation, fibrosis, and inflammation show promise for reversing kidney disease and renal failure.

Area of Science:

  • Nephrology
  • Renal Pathology
  • Translational Medicine

Background:

  • Renal fibrosis is a key factor in progressive kidney disease.
  • Recent experimental evidence suggests fibrosis progression may be reversible.
  • Understanding mechanisms of progression and regression is crucial for human nephropathies.

Purpose of the Study:

  • To review new insights into the mechanisms of renal disease progression and regression.
  • To examine the feasibility and transferability of novel findings to human kidney diseases.
  • To explore therapeutic strategies for reversing renal fibrosis.

Main Methods:

  • Review of recent experimental studies on renal fibrosis.
  • Analysis of agents targeting specific molecular pathways.

Related Experiment Videos

  • Evaluation of evidence for therapeutic interventions.

    • Main Results:

    • Most studies focused on prevention rather than reversal of renal disease.
    • Agents antagonizing transforming growth factor-beta signaling pathways showed promise.
    • Blockers of tyrosine kinase growth factor receptors and kinin receptor activation yielded interesting results.

    Conclusions:

    • Therapeutic systems targeting simultaneous proliferation, fibrosis, and inflammation are the future.
    • Inhibitors of these mediators can complement classical therapies like angiotensin II blockers.
    • These approaches may achieve regression of renal fibrosis and reversal of renal failure.